Search

Your search keyword '"Ciardiello F"' showing total 140 results

Search Constraints

Start Over You searched for: Author "Ciardiello F" Remove constraint Author: "Ciardiello F" Language undetermined Remove constraint Language: undetermined
140 results on '"Ciardiello F"'

Search Results

1. Clinical management of metastatic colorectal cancer in the era of precision medicine

2. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

Catalog

Books, media, physical & digital resources

3. Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population

4. Diagnostic value/performance of radiological liver imaging during chemoterapy for gastrointestinal malignancy: a critical review

5. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

8. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

9. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

11. Adjuvant Chemioradiotherapy in Patients with stage III or IV Radically Resected Gastric Cancer: a pilot study

12. External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life

15. EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER

16. Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor

17. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor

18. chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. Indolfi C, Di Lorenzo E, Rapacciuolo A, Stingone AM, Stabile E, Leccia A, Torella D, Caputo R, Ciardiello F, Tortora G, Chiariello M

19. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonuclotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells

20. Farsighted Stable Sets

22. Effetti della somministrazione sistemica di cAMP sulla proliferazione dele fibrocellule muscolari lisce indotta dal danno vascolare in vivo

25. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst. 1996 Dec 4;88(23):1770-6

28. The cAMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors

29. Inhibition of Cripto expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides

30. Effects of mutant p53 genes on transformation of human mammary epithelial cells

31. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases

34. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells

35. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production

39. Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism

40. Effect of thymic extract 'thymostimulin' on the incidence of infections and myelotoxocity during adjuvant chemotherapy for breast cancer

41. Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up

42. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model

43. 8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer

44. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer

45. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity

46. The rational basis of using novel targeted biological agents in non-small cell lung cancer

47. An update of new targets for cancer treatment: Receptor-mediated signals